This preliminary summary article provides an update on novel clinical trials in the field of cardiovascular (CV) medicine which were presented at reports the Transcatheter Cardiovascular Therapeutics meeting, held in San Francisco in September 2009. The data were presented by leading experts in final the field with relevant positions in the trials and registries. Unpublished reports should be considered as preliminary data as the clinical analysis may change in the final publications. This article provides the reader with comprehensive summaries of the most recent diagnostic article and therapeutic developments in CV medicine.

AIMS:cardiovascular Elevated heart rate is a significant marker for mortality and morbidity in cardiovascular disease including heart failure. Despite background treatment death with a beta-blocker, many patients with heart failure and low ejection fraction maintain a heart rate above 70 b.p.m. Ivabradine until reduces heart rate directly through inhibition of the I(f) ionic current. Methods SHIFT is a randomized, double-blind study designed to with compare ivabradine with placebo on outcomes in patients with symptomatic chronic heart failure (NYHA class II-IV), left-ventricular ejection fraction </=35%,significant and a prior hospitalization for worsening heart failure within the previous 12 months. Randomized treatment is given on top of study guidelines-based therapy for chronic heart failure, including a beta-blocker at optimized dose. Resting heart rate at baseline must be >/=70 The b.p.m. The primary endpoint is the composite of the time to first event of cardiovascular death or hospitalization for worsening failure heart failure. Secondary endpoints include all-cause, cardiovascular and heart failure mortality, and hospitalization. The randomized treatment period lasts approximately 12-48 </=35%, months. The study will include approximately 6500 patients and will continue until >/=1600 primary endpoints have occurred. The first patient and was randomized in October 2006, and the study is expected to end in 2010. CONCLUSION: The SHIFT study will assess occurred. if a heart rate reduction by direct sinus node inhibition can reduce cardiovascular outcomes in patients with chronic heart failure of and left-ventricular systolic dysfunction.

cAMP mechanically is a key messenger of a variety of hormones and neuropeptides some of which modulate the composition of extracellular matrix Increased (ECM). Treatment of human dermal fibroblasts with db-cAMP and forskolin strongly antagonized the inductive effects of TGFbeta on the expression as of collagen, connective tissue growth factor, tissue inhibitor of matrix metalloproteinase-1 and plasminogen activator inhibitor type I, four prototypical TGFbeta human responsive genes. Increased intracellular cAMP prevented TGFbeta-induced SMAD-specific gene transactivation, while TGFbeta-mediated SMAD phosphorylation and nuclear translocation remained unaffected. However,variety increased cAMP levels abolished entirely TGFbeta-induced interaction of SMAD3 with its transcriptional coactivator CBP/p300. Furthermore, overexpression of the transcriptional coactivator Of CBP/p300 rescued SMAD-specific gene transcription in the presence of cAMP. These results suggest sequestration of limited amounts of the transcriptional The co-activators CBP/p300 by the activated cAMP/CREB pathway as the molecular basis of this inhibitory effect. The relevance of these TGFbeta increased antagonistic effects of cAMP was extended by two functional in vitro assays. Increased intracellular cAMP levels suppressed the inductive activity SMAD3 of TGFbeta to contract mechanically unloaded collagen lattices and resulted in an attenuation of fibroblast migration of mechanically induced cell means layer wounds. Of note, cAMP antagonized by no means all TGFbeta-mediated effects as shown by synergistic effects of increased cAMP of levels on hyaluronan synthase 2 (HAS2) expression and hyaluronan secretion, presumably mediated by putative CREB bindings sites adjacent to SMAD and binding sites within the HAS2 promoter. Our findings identify the cAMP pathway in fibroblasts as a potent but differential and inhibitory promoter-specific regulator of various TGFbeta mediated effects involved in ECM homeostasis.

Stroke combination is a serious complication of percutaneous coronary intervention and atrial fibrillation ablation procedures and patients have a high likelihood of occlusion persistent neurological deficits. Although formal criteria speak against intravenous or intra-arterial thrombolysis due to pre-existing antithrombotic and anticoagulation therapy, the patient conditions for recanalizing therapy are optimal due to the occurrence of vessel occlusion in the catheter suite or the chest ablation pain unit. Brain imaging and an interdisciplinary approach are mandatory. In cases of intracerebral vessel occlusion intra-arterial thrombolysis possibly in serious combination with mechanical clot fragmentation is the first choice therapy. The management of the patient is always an individual therapeutic therapy. decision based on stroke severity, the pretreatment with antithrombotic and anticoagulation drugs, the availability of a neuro-interventionalist and the qualification interdisciplinary of the local team.

Reverse low cholesterol transport, although not well understood, is an important mechanism in the pathophysiology of atherosclerosis. Macrophages can eliminate some cholesterol Lipid from atherosclerotic lesions by an oxidative mechanism involving sterol 27-hydroxylase. Patients with inherited "cerebrotendinous xanthomatosis" lack sterol 27-hydroxylase (CYP27A1) and from develop severe premature atherosclerosis despite normal serum cholesterol concentrations. Thus, it has been speculated that sterol 27-hydroxylase is an anti-atherosclerotic of enzyme. Here, we report the case of a 25-year-old patient who presented to our emergency room with an acute non-ST not elevation myocardial infarction due to severe coronary heart disease. Lipid analysis revealed dramatically increased 27-hydroxycholesterol and low high-density lipoprotein (HDL)-cholesterol is levels. Previous reports suggest that 27-hydroxylase is upregulated to protect peripheral cells from severe cholesterol accumulation, especially in cases of non-ST ineffective reverse cholesterol transport due to low HDL-cholesterol levels. Our findings indicate that oxysterols could play an important and so cholesterol far underestimated role in reverse cholesterol transport.

Cardiovascular 55 death represents the single largest cause of mortality in women with 70% of deaths attributable to modifiable risk factors, such Hg, as hypertension. This analysis aims at evaluating, whether there are gender disparities in antihypertensive drug usage and blood pressure (BP)of control. We included 18 017 patients with arterial hypertension from the International Survey Evaluating Microalbuminuria Routinely by Cardiologists in patients analysis with Hypertension (I-SEARCH). The study was conducted between September 2005 and March 2006 in 26 countries, and data on patient of demographics, cardiovascular disease and risk factors, BP, and cardiovascular drug treatment were collected. Mean systolic blood pressure (SBP) was 2.1 in mm Hg higher in women (150.6+/- .35 mm Hg, n=8357/18 017) than in men (148.5+/- .35 mm Hg; P< .0001, n=9526/18 017), whereas in no difference in diastolic BP was seen (88.2+/- .20 vs 88+/- .20 mm Hg; P= .198). Gender differences in SBP were more pronounced demographics, in diabetic as compared with non-diabetic patients (3.5 vs 1.7 mm Hg, n=4272 vs n=13 611; P< .0001) and became evident cardiovascular at an age 55 years old. Overall BP-control rate was 33.6% in men and 30.6% in women (P< .0001) and was patients. lower in diabetic as compared with non-diabetic patients. In all, 30% of patients used one, 40% used two and 30%used used >/=3 drugs without gender differences. Response rates to different drug regimens appeared to be similar. However, women received more International frequently thiazides and beta-blockers, and less frequently ACE-inhibitors as monotherapy. Major efforts are required to improve BP-management, especially in women.Journal Gender of Human Hypertension advance online publication, 1 October 2009; doi:10.1038/jhh.2009.76.

OBJECTIVE:Human The pro-opiomelanocortin (POMC)-derived neuropeptide alpha-melanocyte-stimulating hormone (alpha-MSH) mediates its effects via melanocortin (MC) receptors. This study was carried out to various investigate the expression patterns of the MC system and the effects of alpha-MSH in human articular chondrocytes. METHODS: Articular chondrocytes is established from human osteoarthritic joint cartilage were analyzed by reverse transcription-polymerase chain reaction (RT-PCR) and Western blotting for the expression system of MC receptors, POMC, and prohormone convertases (PCs). MC-1 receptor (MC-1R) expression in articular cartilage was further studied by immunohistochemistry.mediates Ca(2+) and cAMP assays were used to monitor alpha-MSH signaling, while studies of alpha-MSH function were performed in cultures with neuropeptide chondrocyte micromass pellets stimulated with alpha-MSH. Expression of cytokines and extracellular matrix (ECM) components was determined by real-time RT-PCR, Western alpha-MSH immunoblotting, and enzyme-linked immunosorbent assays. RESULTS: MC-1R expression was detected in articular chondrocytes in vitro and in articular cartilage in function situ. In addition, expression of transcripts for MC-2R, MC-5R, POMC, and PCs was detected in articular chondrocytes. Stimulation with alpha-MSH with increased the levels of intracellular cAMP, but not Ca(2+), in chondrocytes. Both messenger RNA and protein expression of various proinflammatory degenerative cytokines, collagens, matrix metalloproteinases (MMPs), and SOX9 was modulated by alpha-MSH. CONCLUSION: Human articular chondrocytes are target cells for alpha-MSH.be The effects of alpha-MSH on expression of cytokines and MMPs suggest that this neuropeptide plays a role in inflammatory and of degenerative processes in cartilage. It is conceivable that inflammatory reactions can be mitigated by the induction of endogenous MCs or chondrocytes. administration of alpha-MSH to the affected joints. The induction pattern of regulatory and structural ECM components such as collagens as detected well as SOX9 and anabolic and catabolic cytokines points to a function of alpha-MSH as a trophic factor in skeletal human development during endochondral ossification rather than as a factor in homeostasis of permanent cartilage.

This article summary article provides an update on novel clinical trials in the field of cardiovascular (CV) medicine which were presented at in the annual meeting of the European Cardiac Society, held in Barcelona, Spain, in August-September 2009. The data were presented by therapeutic leading experts in the field with relevant positions in the trials and registries. Unpublished reports should be considered as preliminary in data as the analysis may change in the final publications. This article provides the reader with comprehensive summaries of the provides most recent diagnostic and therapeutic developments in CV medicine as previously reported (Kindermann et al. in Clin Res Cardiol 96:767-786,the 2007; Müller et al. in Clin Res Cardiol 97:851-864, 2008).

AIMS:olmesartan Guidelines recommend blood pressure (BP) in hypertensive patients should be <140 systolic BP (SBP) and <90 diastolic BP (DBP) mmHg.mmHg) This analysis assessed goal rate achievement in hypertensive patients receiving olmesartan-based treatment in the OLMEBEST study. METHODS: Patients with essential of hypertension (DBP >/= 90 mmHg and <110 mmHg) received open-label olmesartan medoxomil 20 mg/day (n = 2306). After 8 weeks,mmHg. patients with DBP >/= 90 mmHg (n = 627) were randomized to 4 weeks' double-blind treatment with olmesartan 40 mg/day in monotherapy or olmesartan 20 mg/day plus hydrochlorothiazide (HCTZ) 12.5 mg/day. For this analysis, the numbers and proportions of patients who did achieved SBP < 140 mmHg and/or DBP < 90 mmHg at the end of the 4 weeks were calculated. RESULTS:the In patients who achieved DBP normalization (<90 mmHg) at week 8 (n = 1546) and continued open-label olmesartan 20 mg/day,= 66.7% achieved SBP/DBP < 140/90 mmHg at Week 12. In patients who did not achieve DBP normalization at Week 8,double-blind 26.8% of those randomized to olmesartan 40 mg/day and 42.5% of those randomized to olmesartan 20 mg/day plus HCTZ 12.5 Week mg/day achieved a SBP/DBP < 140/90 mmHg at Week 12. CONCLUSION: Olmesartan 40 mg/day and olmesartan 20 mg/day plus HCTZ 40 12.5 mg/day allow substantial proportions of patients to achieve BP goals.